| 625 |
Adverse Drug Reactions(ADRs) to First Line Treatment |
Live |
25/03/2022 |
| 626 |
Adverse Drug Reactions(ADRs) to Second Line Treatment |
Live |
25/03/2022 |
| 622 |
DSTB Treatment Phases |
Live |
25/03/2022 |
| 621 |
DS-TB Treatment – Patient Flow |
Live |
25/03/2022 |
| 592 |
Drug-Sensitive Tuberculosis(DS-TB) |
Live |
25/03/2022 |
| 617 |
Patient – TB Aarogya Sathi Application |
Live |
25/03/2022 |
| 616 |
Citizen – TB Aarogya Sathi Application |
Live |
25/03/2022 |
| 134 |
Nikshay interfaces- Web and Mobile application |
Live |
25/03/2022 |
| 610 |
Long Term Post-treatment follow up of TB patients |
Live |
25/03/2022 |
| 121 |
Classification of TB cases based on history of Previous TB treatment |
Live |
25/03/2022 |
| 600 |
Categorization of TB Treatment Regimen |
Live |
25/03/2022 |
| 565 |
Interaction of Health Volunteers with TB Patient care ecosystem |
Live |
25/03/2022 |
| 518 |
Patient interaction with TB Care Ecosystem |
Live |
24/03/2022 |
| 336 |
Environmental influences in TB |
Live |
24/03/2022 |
| 586 |
Agent factors in TB |
Pending Review |
24/03/2022 |
| 582 |
Chemotherapy and its implication in TB control |
Live |
24/03/2022 |
| 259 |
Linkages to Social Welfare Schemes |
Pending Review |
24/03/2022 |
| 574 |
Linkages to Social Support Scheme |
Pending Review |
24/03/2022 |
| 563 |
FDCs used in NTEP |
Live |
23/03/2022 |
| 562 |
Advantages of FDCs |
Live |
23/03/2022 |
| 240 |
Fixed Dose Combinations [FDC]s |
Live |
23/03/2022 |
| 239 |
Treatment Phases |
Live |
22/03/2022 |
| 237 |
First line anti TB drugs |
Live |
22/03/2022 |
| 550 |
Role of Health Volunteers in TB Case Finding |
Live |
22/03/2022 |
| 542 |
Sputum Collection Process |
Live |
22/03/2022 |
| 538 |
Presumptive Paediatric TB |
Live |
21/03/2022 |
| 537 |
Presumptive EP-TB |
Live |
21/03/2022 |
| 536 |
Presumptive Pulmonary TB |
Live |
21/03/2022 |
| 522 |
Symptoms of TB Disease |
Live |
11/03/2022 |
| 94 |
Risk Factors for TB Disease |
Live |
10/03/2022 |
